← All trials
NCT06485258
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 5, 2024
- Primary completion
- Feb 14, 2025
- Completion date
- Oct 14, 2025
- First posted
- Jul 3, 2024
- Last posted
- Aug 12, 2024
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Centers for Disease Control and Prevention (CDC)Lead sponsor
- Bill and Melinda Gates FoundationCollaborator
- University of CincinnatiCollaborator
- Emory UniversityCollaborator
- Emory UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.